The Effects of Sulphanomide-E Derivative on Carnitine Metabolism of Cervix Cancer Cells

Abstract

Introduction: Cervical cancer is one of the most common types of cancer in women worldwide. Recent studies have shown that metabolic programming can support cervical cancer treatment by increasing sensitivity to chemotherapy and radiotherapy. Therefore, the investigation of new treatment agents targeting the metabolism of cervical cancer is of great importance in terms of improving treatment outcomes and developing new strategies. In our previous studies, we determined that Sulfanomide-E derivative has an apoptotic effect on HELA cells. In this study, we aimed to investigate the effects of Sulfanomide-E on carnitine metabolism in HELA cells. Method: HELA cells were used in our study and the cytotoxic and apoptotic effects of Sulfanomide-E were investigated. A dose of 25 μg/ml Sulfanomide-E was applied to HELA cells and the cells were incubated for 24 hours. In order to determine the changes in carnitine metabolism, a total of 27 carnitine and acylcarnitine derivatives were analyzed using LC-MS/MS. The obtained data were analyzed with SPSS 25.0 program. Findings: As a result of the analyses, a significant increase was observed in all carnitine and acylcarnitine derivatives in the Sulfanomide-E applied groups compared to the control group. These findings indicate that Sulfanomide-E has an effect on carnitine metabolism and these metabolic changes may be important in terms of response to treatment. Conclusion: This study reveals that Sulfanomide-E affects carnitine metabolism in HELA cells and exhibits apoptotic effects. The obtained data suggest that these changes in carnitine metabolism may provide a new understanding of the potential benefits of metabolic programming in the treatment of cervical cancer. Therefore, the role of agents such as Sulfanomide-E in the treatment of cervical cancer should be supported by more detailed studies.